ATENOLOL 100 MG
ATENOLOL : 100 MG · DIN 02238318 · SIVEM PHARMACEUTICALS ULC
Health Canada status: MARKETED
What is ATENOLOL?
ATENOLOL 100 MG contains ATENOLOL : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02238318, held by SIVEM PHARMACEUTICALS ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 05-Jan-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is ATENOLOL called?
The same molecule, ATENOLOL, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Atenolol Viatris | Latin | Norway, Sweden |
| ATENOLAB | Latin | Brazil |
| Betaten | Latin | Bahrain, Saudi Arabia |
| Atenolol Medical Valley | Latin | Norway, Sweden |
| Tenormin | Latin | Australia, Bahrain |
| ZOTROL | Latin | Morocco |
| ANGIPRESS | Latin | Brazil |
| ABLOK | Latin | Brazil |
| Atenolol Accord | Latin | Sweden |
| Atenolol Orifarm | Latin | Sweden |
| Atenolol Teva | Latin | Sweden |
| ATENOR | Latin | Morocco |
| TENORMINE | Latin | Morocco |
| XYTENOL | Latin | Morocco |
| APX-Atenolol | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02238318 |
|---|---|
| Brand name | ATENOLOL |
| Generic / active ingredient | ATENOLOL : 100 MG |
| Manufacturer | SIVEM PHARMACEUTICALS ULC |
| Strength | 100 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C07AB03 ATENOLOL |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 05-Jan-2024 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02238318 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2238318 |
| Brand name | ATENOLOL |
| Active ingredient / INN | ATENOLOL : 100 MG |
| ATC code | C07AB03 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C07 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | SIVEM PHARMACEUTICALS ULC |
Which pack is which?
| Strength on the label | 100 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Is ATENOLOL in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C07AB03 ATENOLOL. 28 of 87 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-ATENOL TAB 100MG | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 00773697 |
| APO-ATENOL TAB 50MG | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 00773689 |
| ATENOLOL | 100 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 00828793 |
| ATENOLOL | 25 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02541564 |
| ATENOLOL | 25 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02326701 |
| ATENOLOL | 50 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 00828807 |
| ATENOLOL | 50 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02238316 |
| JAMP-ATENOLOL | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02367572 |
| JAMP-ATENOLOL | 25 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02367556 |
| JAMP-ATENOLOL | 50 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02367564 |
Who else supplies ATENOLOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ATENOLOL appears in 359 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does ATENOLOL cost around the world?
ATENOLOL is listed on 16 national price registers Nexara tracks, across 338 pack listings published on 14 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Brazil | preco fabrica (ex-factory ceiling) | 7 | 67 | 02 Sep 2026 |
| United States | acquisition | 3 | 53 | 03 Sep 2026 |
| Saudi Arabia | public | 34 | 41 | 01 Sep 2026 |
| South Africa | single exit price | 29 | 31 | 01 Sep 2026 |
| Spain | PVP con IVA (public price) | 27 | 27 | 05 Sep 2026 |
| Morocco | PPV (public price) | 8 | 20 | 05 Sep 2026 |
| Australia | ex-manufacturer | 9 | 18 | 08 Sep 2026 |
| Bahrain | retail (max) | 6 | 16 | 01 Sep 2026 |
| United Arab Emirates | public | 10 | 15 | 31 Aug 2026 |
| Sweden | AIP (pharmacy purchase price) | 5 | 15 | 03 Sep 2026 |
| Norway | max AUP (pharmacy retail) | 2 | 11 | 07 Sep 2026 |
| Romania | max producer price | 6 | 8 | 03 Sep 2026 |
| Belgium | public | 6 | 6 | 01 Sep 2026 |
| United Kingdom | hospital | 4 | 4 | 31 Aug 2026 |
| Greece | producer price (ex-factory) | 4 | 4 | 03 Sep 2026 |
| Slovakia | categorised final price | 2 | 2 | 02 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.